News
Tuesday, September 17th, 2013
Wiley: 9/12/13 Limited studies exist on the outcome of thrombolytic therapy of acute ischemic stroke patients outside of clinical trials. Aim To assess the possible risk factors associated with in-hospital death and symptomatic intracerebral hemorrhage among patients who received intravenous tissue plasminogen activator. Methods A total of 7193 patients with a clinical diagnosis of acute ischemic […]
News
Tuesday, September 17th, 2013
Wiley: 9/5/13 Data on cardiac complications and their precipitants after intracerebral hemorrhage are scarce. We examined the frequency and risk factors for serious in-hospital cardiac events in a large cohort of consecutive intracerebral hemorrhage patients. Methods A retrospective chart review of 1013 consecutive patients with nontraumatic intracerebral hemorrhage treated at the Helsinki University Central Hospital (2005–2010). […]
News
Tuesday, September 17th, 2013
STROKEAHA: September 5, 2013 Background and Purpose—Lacunar infarction is attributable to a perforating arteriolar abnormality. Possible causes include embolism, atheromatosis, or intrinsic disease. We examined whether the size, shape, or location of the lacunar infarct varied with embolic sources, systemic atheroma, or vascular risk factors. Methods—We examined data from 3 prospective studies of patients with clinical […]
Atrial Fibrillation
Thursday, September 5th, 2013
JACC: September 10, 2013 Objectives The purpose of this study was to investigate the risk of thrombosis and bleeding according to multiple antithrombotic treatment regimens in atrial fibrillation (AF) patients after myocardial infarction (MI) or percutaneous coronary intervention (PCI). Background The optimal antithrombotic treatment strategy is unresolved in patients with multiple indications. Methods A total of 12,165 AF […]
Atrial Fibrillation
Thursday, September 5th, 2013
atrialfibrillationblog: 9/5/13 What you don’t know about atrial fibrillation could kill you, or a loved one! Atrial fibrillation (also called afib) is an irregular heartbeat (or heart rhythm), and is a major cause of strokes. Having afib increases your stroke risk by 500 percent. In addition, afib can lead to heart failure, dementia, and even Alzheimer’s […]
Atrial Fibrillation
Thursday, September 5th, 2013
J Am Heart Assoc.: September 3, 2013 Background Atrial fibrillation (AF) patterns and their relations with long‐term prognosis are uncertain, partly because pattern definitions are challenging to implement in longitudinal data sets. We developed a novel AF classification algorithm and examined AF patterns and outcomes in the community. Methods and Results We characterized AF patterns between 1980 and […]
Atrial Fibrillation
Thursday, September 5th, 2013
Medicalxpress: 9/1/13 Patients with five or more risk factors have the same stroke risk as patients with atrial fibrillation, according to research presented at the ESC Congress today by Dr. Christine Benn Christiansen from Denmark. The study included data on more than 4 million patients from Danish registries over a 10 year period. Dr Benn Christiansen […]
Atrial Fibrillation
Thursday, September 5th, 2013
Aug. 31, 2013 — General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that women were undertreated with antithrombotic medications compared to men regardless of their stroke risk and comorbidities. Dr Sabouret said: […]
Clinical Trials
Thursday, September 5th, 2013
STROKEAHA: September 3, 2013 Background and Purpose—The practicalities of doing ambulance-based trials where paramedics perform all aspects of a clinical trial involving patients with ultra-acute stroke have not been assessed. Methods—We performed a randomized controlled trial with screening, consent, randomization, and treatment performed by paramedics prior to hospitalization. Patients with probable ultra-acute stroke (<4 hours) and […]
Clinical Trials
Thursday, September 5th, 2013
Nejm: 9/1/13 In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of […]
